Shmuel Shoham, MD
Disclosures: Contracted Research-Ansun-Principal_Investigator|Contracted Research-cidara-Principal_Investigator|Contracted Research-Merck and Company, Inc.-Principal_Investigator|Contracted Research-F2G-Principal_Investigator|Contracted Research-Astellas-Principal_Investigator|Contracted Research-Shire-Other_Role-sub investigator|Consulting Fee-Reviral-Other_Role-consultant|Consulting Fee-acidophil-Other_Role-consultant |Consulting Fee-amplyx-Other_Role-consultant|Consulting Fee-Janssen-Other_Role-consultant|Contracted Research-Reviral-Principal_Investigator|DSBM-Karyopharm-Other_Role-DSMB chair|DSBM-Intermountain Health-Other_Role-DSMB member - 06/16/2020

Shmuel Shoham, MD is Professor of Medicine at Johns Hopkins University School of Medicine. He received his medical degree from Thomas Jefferson University (Philadelphia, PA) and completed his medical residency and infectious diseases fellowship training at Boston University School of Medicine. Dr. Shoham has over 20 years of experience in management of immunocompromised patients with invasive infections and is a member of the Transplant and Oncology Infectious Diseases program at Johns Hopkins. He has served as an investigator, consultant and data safety monitoring board member for multiple interventional COVID-19 therapeutics trials. He is a member of guideline panels for COVID-19 therapy for the Infectious Diseases Society of America (IDSA) and the National Comprehensive Cancer Network (NCCN) and is a member of the Vaccines and Therapeutics Taskforce for the Lancet Commission on COVID-19.